Back to HGSI Stock Lookup
Pages: 1 2 »» Last Page

Human Genome Sciences, Inc. (HGSI) – Corporate News

Jul 10, 2012 07:03 AM Human Genome (HGSI) Announces Resubmission of Raxibacumab BLA; PDUFA Date Set for Dec. 15th
Jun 29, 2012 09:11 AM Human Genome (HGSI) Says Less than 1% of Shares Tendered in Glaxo (GSK) Offer
Jun 29, 2012 07:09 AM Glaxo (GSK) Extends $13/Share Tender for Human Genome (HGSI)
Jun 15, 2012 07:12 AM ATTENTION, GLAXO (GSK): Human Genome's (HGSI) Cut-Off Date is July 16th, Will Provide Details to Interested Parties
Jun 15, 2012 06:41 AM Human Genome Sciences (HGSI) Calls It; Says July 16th Deadline for Bids (GSK)
Jun 8, 2012 09:28 AM Human Genome (HGSI) Rejects $13/Share Bid from Glaxo (GSK); Calls It 'Inadequate'
Jun 8, 2012 09:27 AM Human Genome (HGSI) Comments on GlaxoSmithKline's (GSK) Announcement to Extend Tender Offer
Jun 8, 2012 08:38 AM UPDATE: GlaxoSmithKline (GSK) Extends Tender Offer for Human Genome (HGSI) to June 29th
May 17, 2012 01:17 PM Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
May 9, 2012 10:08 AM Human Genome Sciences (HGSI) to Review Offer from Glaxo (GSK)
Apr 3, 2012 07:46 AM Human Genome (HGSI) Affirms New Albiglutide from Glaxo (GSK)
Jan 9, 2012 07:05 AM Human Genome Sciences (HGSI) Announces 2012 Priority Goals and Updates Commercialization of BENLYSTA
Dec 12, 2011 08:10 AM Barron's Sees Human Genome (HGSI) Shares Doubling Over Next 18 Months
Nov 17, 2011 03:59 PM Disappointing Trial Results on Albiglutide Make Glaxo Bid for Human Genome Less Likely -RBC (GSK) (HGSI)
Nov 3, 2011 07:15 AM Human Genome (HGSI) Underwriters Exercise Full Option Under $430M Notes Offering
Nov 2, 2011 07:36 AM Human Genome (HGSI) Announces $400M Convertible Senior Notes Offering
Sep 21, 2011 10:14 AM Human Genome (HGSI) Shares Higher as Aug. Benlysta Sales Strong
Aug 24, 2011 12:23 PM Human Genome (HGSI) Shares Lower Amid Concerning Benlysta Sales for July; Analyst Sees Potential Glaxo Bid at a Discount (GSK)
Jul 14, 2011 06:32 AM Glaxo (GSK), Human Genome (HGSI) BENLYSTA Granted Marketing Authorization in Europe
May 20, 2011 06:34 AM Glaxo (GSK), Human Genome (HGSI) Recieve Positive Opinion from CHMP for BENLYSTA
Apr 14, 2011 06:40 AM Human Genome (HGSI) to Update on BENLYSTA; Guides R&D and SG&A Expense for FY11
Mar 16, 2011 04:04 PM Human Genome Sciences (HGSI), FivePrime Announce Pact for Licensing Rights to FP-1039 in US, Canada
Mar 10, 2011 08:13 AM Human Genome (HGSI) Could Miss 30% of Lupus Market with Benlysta on Uncertain Data
Mar 9, 2011 05:42 PM FDA Approves Human Genome (HGSI) Lupus Treatment Benlysta (GSK)
Jan 10, 2011 07:42 AM Human Genome (HGSI) Updates on Expectations Heading into 2011
Dec 3, 2010 04:05 PM Human Genome Sciences (HGSI), Glaxo (GSK) Say FDA Extends PDUFA Date for Benlysta to March 10
Nov 16, 2010 05:50 PM Human Genome (HGSI) Shares Resume Trading Up 12%
Nov 16, 2010 05:37 PM Human Genome (HGSI) shares to resume trading at 5:50pm ET
Oct 5, 2010 06:56 AM Human Genome Sciences (HGSI) Receives FDA Complete Response Letter for ZALBIN
Sep 28, 2010 08:57 AM Morphotek Announces Selection of Monoclonal Antibody to Clinically Develop in Human Genome (HGSI) Collaboration
Aug 19, 2010 07:25 AM Human Genome (HGSI), Glaxo (GSK) report FDA priority review for Benlysta for Lupus; Says PDUFA date Dec. 9
Aug 19, 2010 07:24 AM Human Genome (HGSI) and Glaxo (GSK) Receive U.S. FDA Priority Review for SLE Treatment BENLYSTA
Jun 17, 2010 07:06 AM Human Genome (HGSI) and Glaxo (GSK) Announces Strong Results in BENLYSTA BLISS-52 Study
Jun 14, 2010 06:51 AM Human Genome Sciences (HGSI) Gets Response from U.S. FDA for ZALBIN BLA
Jun 10, 2010 06:49 AM Human Genome (HGSI) SUbmits BLA to U.S. FDA for BENLYSTA SLE Treatment
Jun 9, 2010 07:24 AM Human Genome (HGSI) Announces Flat Results of HGS-ETR1 in Combo with Velcade
Jun 7, 2010 06:52 AM Human Genome (HGSI) Announces Glaxos Submitted an MAA for BENLYSTA to U.S. FDA
Apr 20, 2010 07:53 AM Human Genome (HGSI) and Glaxo (GSK) Announce Positive Pivitol BLISS-76 Phase 3 Results
Apr 19, 2010 07:18 AM Human Genome (HGSI) Announces Novartis Withdrawals MAA for JOULFERON HCV Treatment from EMA
Mar 24, 2010 07:15 AM Human Genome Sciences (HGSI) Announces Interim Results for ZALBIN Phase 2b on Patients with Hep C
Mar 17, 2010 07:05 AM Human Genome (HGSI) Announces Results of HGS-ETR1 Phase 2; Shows No Difference from Mapaumumab Vs. Control Group
Jan 11, 2010 08:21 AM BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
Dec 8, 2009 11:52 AM Human Genome (HGSI) Closes 17.83M Common Offering
Nov 25, 2009 07:18 AM Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
Nov 16, 2009 07:24 AM Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
Oct 27, 2009 03:55 PM Panel Says Human Genome's (HGSI) Raxibacumab Needs More Testing
Oct 27, 2009 02:34 PM FDA Panel Weighing If Human Genome's (HGSI) Drug Needs More Study
Oct 20, 2009 07:32 AM Human Genome (HGSI) and Glaxo (GSK) Announce BLISS-52 Lupus Treatment Results
Oct 19, 2009 07:06 AM Human Genome (HGSI) Receives $75M Payment from Novartis AG (NVS) for Zalbin Hep C Treatment
Sep 21, 2009 10:40 AM Human Genome Sciences (HGSI) CEO Said Lupus Drug Could Sell for $20,000/Yr or More
Pages: 1 2 »» Last Page

Back to HGSI Stock Lookup